Company profile
Grown Rogue International Inc.
OTC: GRUSF · Healthcare · Drug Manufacturers - Specialty & Generic
#491 of 1,422 Healthcare companies by revenue68th-percentile growth
EA Score
52DFH 83DQ 2GM —SS 67
v0.1 · 55/100 weight · provisional
↑ Altman-Z, Piotroski F · ↓ disclosure history, filing timeliness
Methodology →Revenue TTM
$9.2T
Rev growth YoY (TTM)
+38500460.9%
Net income (FY)
$3.2M
Employees
204
as of 2026-08-18
Market cap
$112.0M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$32.4M$32.4M2025
Net income$3.2M$3.2M2025
Operating income-$593.5k-$593.5k2025
Total assets$62.7M$62.7M2025
Liabilities$38.8M$38.8M2025
Equity$20.9M$20.9M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Grown Rogue International Inc.’s revenue?
Grown Rogue International Inc. booked $32.4M in FY2025 revenue, growing 22% year over year — faster than most Healthcare companies we track, at a 10.0% net margin.
Peers · Healthcare
Orchestra BioMed Holdings, Inc.46DArcus Biosciences, Inc.47DC21 Investments Inc.49DStereotaxis, Inc.55CAoxing Pharmaceutical Company, Inc.——MediPharm Labs Corp.61CKey facts
CEOJ. Obie Strickler
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersMedford, OR
ExchangeOTC: GRUSF
Employees204
IPO date2010-10-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.